Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Arvinas logo — Leading the way in targeted protein degradation therapeutics

Arvinas

Leading the way in targeted protein degradation therapeutics

Founded 2013 United States New Haven, United States 305 employees Unknown Total: $585.85M Biotechnology, Health Care +2

General Information

Company Name Arvinas
Founded Year 2013
Location United States New Haven, United States +1
Founders / Decision Makers
Team member Team member Team member
Employees 305
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Unknown
Social

Get notified when Arvinas moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Arvinas

Arvinas is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in the United States. The company is committed to developing targeted protein degradation therapeutics with the aim of improving the lives of patients suffering from debilitating and life-threatening diseases. Their proprietary PROTAC® Discovery Engine platform enables the engineering of PROTAC® targeted protein degraders, which leverage the body’s natural protein disposal system to selectively degrade and remove disease-causing proteins. Arvinas boasts a robust preclinical pipeline of PROTAC® protein degraders targeting validated and “undruggable” proteins and has two clinical-stage programs: ARV-110 for metastatic castrate-resistant prostate cancer and ARV-471 for locally advanced or metastatic ER+\/HER2- breast cancer. One of the notable achievements of Arvinas is the $350.00M Post-IPO Equity investment received on 27 November 2023. The investment was made by prominent firms such as RA Capital Management, Boxer Capital, ArrowMark Partners, BB Biotech Ventures, EcoR1 Capital, RTW Investments, Great Point Partners, Citadel Global Equities, Surveyor Capital, and Avidity Partners. In summary, Arvinas stands at the forefront of biotechnology and pharmaceutical industries, offering innovative therapies and attracting substantial investments to support its groundbreaking research and development efforts. For more information, visit www.arvinas.com.

Taxonomy: biopharmaceutical, protein degradation, therapeutics, clinical-stage, disease treatment, PROTAC® Discovery Engine platform, proteolysis targeting chimeras, metastatic castrate-resistant prostate cancer, locally advanced breast cancer, metastatic ER+/HER2- breast cancer, drug discovery, autoimmune diseases, rare diseases, cancer therapy, preclinical pipeline

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Private Placement Vc •••••• - 01 Nov 2023
IPO •••••• - 01 Sep 2018
Series C •••••• 9
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Apr 2018
Spinout •••••• 1
Investor
01 Jan 2017
Series B •••••• 5
Investor Investor Investor Investor
•••• •••• 		01 Oct 2015

View All 6 Funding Rounds

Latest News

View All
Alentis doubles down on Claudin1 | ApexOnco - Clinical Trials news and analysis — Oncologypipeline.com
Alentis doubles down on Claudin1 | ApexOnco - Clinical Trials news and analysis
Oncologypipeline.com Sep 25, 2025

Arvinas Alternatives & Competitors

Arvinas vs
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. United States

Clinical-stage biotech company transforming how disease is treated through targeted protein degradat...

IPO
111 employees
Biotechnology, Health Care
Compare Arvinas vs C4 Therapeutics, Inc.
Arvinas vs
SEED Therapeutics
SEED Therapeutics United States

Pioneering the science of improving human health

Series A
25 employees
Biotechnology, Health and Wellness
Compare Arvinas vs SEED Therapeutics
Arvinas vs
Venenum BioDesign, LLC
Venenum BioDesign, LLC United States

DISCOVERY IS OUR MISSION

27 employees
Biotechnology
Also compare with: Arvinas vs Relay Therapeutics Relay Therapeutics

FAQ About Arvinas

Leading the way in targeted protein degradation therapeutics
Arvinas was founded in 2013.
Arvinas is headquartered in New Haven, United States.
Arvinas operates in the following industries: Biotechnology, Health Care, Health and Wellness, Pharmaceutical.
Arvinas has approximately 305 employees.
Arvinas has completed 6 funding rounds, raising a total of $585.85M. The latest funding stage is Unknown.
Top alternatives and competitors to Arvinas include C4 Therapeutics, Inc., SEED Therapeutics, Venenum BioDesign, LLC, Relay Therapeutics, AGY Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arvinas and C4 Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Arvinas and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy